Best Agrolife Q3 FY26: Revenue down 26%, loss narrows to Rs 12.7 cr

Revenue declinedNet loss reportedEBITDA margin expansionEmphasis of matterContingent liabilities increasedResults View source PDF Explain this filing

BESTAGRO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹18.90

prior close

₹18.73

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+2.5% vs market

Pesticides & Agrochemicals peers, median of 26sector-0.5%+2.5% vs sector

On the reaction day the stock moved 2.5 pts more than Nifty Microcap 250 and 2.5 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-1.2

15m

-0.3

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0-0.5+2.5-0.5+2.5

Next day

+1.2-2.0+3.2-2.3+3.6

-2.4-2.7+0.3-3.9+1.5

-2.6-1.7-0.9-2.9+0.2

-2.5-1.4-1.1-3.5+0.9

-4.3-2.8-1.5-3.0-1.4

-7.9-2.8-5.1-5.1-2.9

15d

-14.3-8.4-5.9-9.3-5.0

-21.2-9.1-12.1-9.7-11.5

-5.9-4.0-1.9-9.1+3.2

-4.9+2.6-7.5-4.3-0.6

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Best Agrolife Q3 FY26: Revenue Rs 202.9 cr, down 26% YoY, hit by erratic rainfall and weak pest demand. 9M revenue Rs 1,101.1 cr vs Rs 1,540 cr. Q3 PAT loss narrowed to Rs 12.7 cr from Rs 24.2 cr; EBITDA turned positive at Rs 3.8 cr from a Rs 5.8 cr loss. 9M PAT Rs 46.1 cr vs Rs 91.8 cr. Inventory cut 24%, OPEX down 36% in Q3. Patented products now 43% of brand sales. Auditor flagged ongoing Income Tax search matter.

Likely market impact

Weak topline but margin recovery, cost cuts, and patented product traction are positives; tax probe overhang remains.